President and Chief Executive Officer, Chairman
Roger Pomerantz is the President and Chief Executive Officer of Seres Therapeutics. Roger was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Roger was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Previously, Roger received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate, Dr. David Baltimore. Subsequently, Roger was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed seven approved infectious disease drugs in important diseases including HIV, HCV, and tuberculosis.
Co-founder Seres Therapeutics, Managing Partner and CEO, Flagship Ventures
Noubar Afeyan is Managing Partner and CEO of Flagship Ventures, an early-stage venture firm. He is a recognized technologist and entrepreneur. During his 25-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build 26 successful life science and technology startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including Affinnova, BIND Therapeutics, BG Medicine, Eleven Biotherapeutics, Pronutria Biosciences, Joule Unlimited and Moderna Therapeutics. Previously, he was a member of the founding team, director and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb). He earned his Ph.D. in Biochemical Engineering from MIT in 1987.
Jackson Professor of Clinical Medicine at Harvard Medical School / Chair of Medicine, Emeritus at Massachusetts General Hospital
Dennis A. Ausiello, MD is the Jackson Distinguished Professor of Clinical Medicine and Director, Emeritus of the MD/PhD Program at Harvard Medical School; he is also Chair of Medicine, Emeritus and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. Dr. Ausiello has made substantial contributions to the knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters and textbooks and served as an editor of Cecil's Textbook of Medicine.
President and CEO, Selecta Biosciences
Werner Cautreels is President and CEO of Selecta Biosciences and was previously CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories. Before becoming the CEO of Solvay Pharmaceuticals, Werner was their Global Head of R&D. Prior to joining Solvay, he was employed by Sanofi, Sterling-Winthrop, and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. He was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA) from 1999-2006. He is currently a director of Selecta and Galapagos NV (Mechelen, Belgium). He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He was born in Antwerp, Belgium, and graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
Senior Counsel, Covington & Burling, LLP
Peter Hutt is a senior counsel in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law. Peter served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country. He has been a member of the Institute of Medicine since it was founded in 1971, and he currently serves on the Panel on the Administrative Restructuring of the National Institutes of Health. He also serves on academic and venture capital advisory boards, and the boards of numerous startup biotechnology companies. He was named by The Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C.
Former Senior Vice President of Business Development and Corporate Licensing, Merck
Richard N. Kender is a retired executive with 35 years of experience in the pharmaceutical industry. He served as Senior Vice President of Business Development and Corporate Licensing at Merck from 2000 until his retirement in 2013. Mr. Kender joined Merck in 1978 and spent his entire professional career at the company in various corporate areas. During his tenure he was actively involved in more than 100 transactions of different sizes and transaction types. He has previously served on the Board of Directors of FoxHollow Technologies Inc., EV3 Inc. and also served on the Board of BioNJ. Mr. Kender holds a BS degree in Accounting from Villanova University and an MBA from Fairleigh Dickinson University.
Chief Financial Officer, Moderna
Lorence is the CFO of Moderna Therapeutics, a pioneer in messenger RNA Therapeutics. He was previously at Goldman Sachs, where he was a managing director and co-head of the U.S. biotechnology investment banking effort. He joined Goldman Sachs in 1999 as a summer associate, and was named managing director in 2008. As a member of the Healthcare Investment Banking Group for nearly 14 years,Lorence’s responsibilities included corporate finance and mergers and acquisitions (M&A) for the pharmaceutical and biotechnology industries, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions. Prior to joining Goldman Sachs, Lorence worked in various medical research and consulting positions concurrent with his graduate studies. Lorence graduated from Harvard University, magna cum laude and Phi Beta Kappa with an AB in Biochemical Sciences in 1995. He also earned an MBA in Healthcare Management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000, and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.